Compare Torrent Pharma with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA FRESENIUS KABI ONCO. TORRENT PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 54.4 22.1 246.0% View Chart
P/BV x 6.5 3.1 209.6% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 TORRENT PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
FRESENIUS KABI ONCO.
Mar-13
TORRENT PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,550176 880.7%   
Low Rs1,14479 1,456.7%   
Sales per share (Unadj.) Rs354.737.7 941.2%  
Earnings per share (Unadj.) Rs40.15.1 786.8%  
Cash flow per share (Unadj.) Rs64.26.7 955.2%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs273.142.5 642.0%  
Shares outstanding (eoy) m169.22158.23 106.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.83.4 112.4%   
Avg P/E ratio x33.625.0 134.5%  
P/CF ratio (eoy) x21.018.9 110.8%  
Price / Book Value ratio x4.93.0 164.8%  
Dividend payout %34.90-   
Avg Mkt Cap Rs m227,89720,135 1,131.9%   
No. of employees `00014.71.2 1,276.0%   
Total wages/salary Rs m11,353703 1,614.4%   
Avg. sales/employee Rs Th4,083.05,176.2 78.9%   
Avg. wages/employee Rs Th772.3610.4 126.5%   
Avg. net profit/employee Rs Th461.3699.6 65.9%   
INCOME DATA
Net Sales Rs m60,0215,963 1,006.6%  
Other income Rs m2,98818 16,602.2%   
Total revenues Rs m63,0095,981 1,053.5%   
Gross profit Rs m13,4931,430 943.5%  
Depreciation Rs m4,086258 1,584.3%   
Interest Rs m3,085-26 -11,864.6%   
Profit before tax Rs m9,3101,216 765.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m2,529342 739.0%   
Profit after tax Rs m6,781806 841.5%  
Gross profit margin %22.524.0 93.7%  
Effective tax rate %27.228.1 96.5%   
Net profit margin %11.313.5 83.6%  
BALANCE SHEET DATA
Current assets Rs m52,6235,102 1,031.5%   
Current liabilities Rs m52,0222,385 2,180.8%   
Net working cap to sales %1.045.6 2.2%  
Current ratio x1.02.1 47.3%  
Inventory Days Days120150 79.7%  
Debtors Days Days76113 67.3%  
Net fixed assets Rs m85,0165,148 1,651.4%   
Share capital Rs m846158 534.9%   
"Free" reserves Rs m45,3766,556 692.2%   
Net worth Rs m46,2226,732 686.6%   
Long term debt Rs m41,115952 4,317.9%   
Total assets Rs m142,43210,388 1,371.1%  
Interest coverage x4.0-45.8 -8.8%   
Debt to equity ratio x0.90.1 628.9%  
Sales to assets ratio x0.40.6 73.4%   
Return on assets %6.97.5 92.3%  
Return on equity %14.712.0 122.6%  
Return on capital %14.214.6 97.2%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m14,5805,298 275.2%   
Fx outflow Rs m3,6001,772 203.1%   
Net fx Rs m10,9803,525 311.5%   
CASH FLOW
From Operations Rs m8,9421,274 701.8%  
From Investments Rs m-47,070-1,204 3,908.8%  
From Financial Activity Rs m34,174-196 -17,426.8%  
Net Cashflow Rs m-3,655-126 2,893.9%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 7.0 0.3 2,340.0%  
FIIs % 12.6 9.6 131.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 9.1 96.7%  
Shareholders   26,511 42,599 62.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DR. DATSONS LABS  BIOCON   FULFORD INDIA  JUBILANT LIFE SCIENCES  AJANTA PHARMA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Nov 15, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - LUPIN COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS